Usefulness of mid regional pro-atrial natriuretic peptide in the exacerbations of chronic obstructive pulmonary disease

Clinica Chimica Acta

Volumn 412, Issue 5-6, 2011, Pages 470-475

  Lacoma, Alicia ^a   Prat, Cristina ^a   Andreo, Felipe ^a   Lores, Luis ^b   Latorre, Irene ^a   Pérez, Miguel ^a   Ruiz Manzano, Juan ^a   Ausina, Vicente ^a   Dominguez, Jose ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Hospital de Sant Boi   (Spain)

Author keywords

COPD; Exacerbation; Pro atrial natriuretic peptide; Prognosis

Indexed keywords

ATRIAL NATRIURETIC FACTOR; STEROID;

AGED; ARTICLE; BACTERIUM ISOLATE; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE TEST; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; OXYGEN THERAPY; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SMOKING;

AGED; ATRIAL NATRIURETIC FACTOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PNEUMONIA; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 78650855779     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.11.032     Document Type: Article

References (55)

1. Donaldson G.C., Wedzicha J.A. COPD exacerbations.1: Epidemiology. Thorax 2006, 61:164-168.
2. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000, 117:398S-401S.
3. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33:1165-1185.
4. Lacoma A., Prat C., Andreo F., Dominguez J. Biomarkers in the management of COPD. Eur Respir Rev 2009, 18:96-104.
5. Dahl M., Vestbo J., Lange P., Bojesen S.E., Tybjaerg-Hansen A., Nordestgaard B.G. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:250-255.
6. de Torres J.P., Cordoba-Lanus E., Lopez-Aguilar C., et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006, 27:902-907.
7. de Torres J.P., Pinto-Plata V., Casanova C., et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008, 133:1336-1343.
8. Patel A.R., Hurst J.R., Wedzicha J.A. The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. Semin Respir Crit Care Med 2010, 31:267-275.
9. Stolz D., Christ-Crain M., Morgenthaler N.G., et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008, 134:263-272.
10. Stolz D., Christ-Crain M., Morgenthaler N.G., et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007, 131:1058-1067.
11. Muller B., Suess E., Schuetz P., et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med 2006, 260:568-576.
12. Clerico A., Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004, 50:33-50.
13. Clerico A., Fontana M., Ripoli A., Emdin M. Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure. Adv Clin Chem 2009, 48:163-179.
14. Clerico A., Recchia F.A., Passino C., Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006, 290:H17-29.
15. Doust J.A., Glasziou P.P., Pietrzak E., Dobson A.J. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004, 164:1978-1984.
16. Felker G.M., Hasselblad V., Hernandez A.F., O'Connor C.M. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422-430.
17. Goetze J.P. Biosynthesis of cardiac natriuretic peptides. Results Probl Cell Differ 2010, 50:97-120.
18. de Bold A.J., Bruneau B.G., Kuroski de Bold M.L. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996, 31:7-18.
19. McGrath M.F., de Bold A.J. Determinants of natriuretic peptide gene expression. Peptides 2005, 26:933-943.
20. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003, 24:341-356.
21. Shen W., Xu X., Ochoa M., Zeballos G.A., Stewart J.M., Hintze T.H. Contribution of the ventricles and the atrial appendages to the elevation of plasma atrial natriuretic factor (ANF) during pacing-induced heart failure in conscious dogs. Basic Res Cardiol 1996, 91:319-328.
22. Stewart J.M., Wang J., Zeballos G.A., Ochoa M., Schustek M., Hintze T.H. Role of tachycardia and V wave wall stress in the release of ANF during volume loading. Am J Physiol 1993, 264:H217-223.
23. de Bold A.J. Cardiac natriuretic peptides gene expression and secretion in inflammation. J Investig Med 2009, 57:29-32.
24. Morgenthaler N.G., Struck J., Thomas B., Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004, 50:234-236.
25. Prat C., Lacoma A., Dominguez J., et al. Midregional pro-atrial natriuretic peptide as a prognostic marker in pneumonia. J Infect 2007, 55:400-407.
26. Barbera J.A., Peces-Barba G., Agusti A.G., et al. Clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease. Arch Bronconeumol 2001, 37:297-316.
27. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
28. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-72.
29. Isenberg H.D. Clinical microbiology procedures handbook, 2nd update ed 2007, ASM Press, Washington.
30. Apple F.S., Panteghini M., Ravkilde J., et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005, 51:486-493.
31. Apple F.S., Wu A.H., Jaffe A.S., et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: analytical issues for biomarkers of heart failure. Circulation 2007, 116:e95-98.
32. Murray P.R., Washington J.A. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc 1975, 50:339-344.
33. Agusti A.G., Noguera A., Sauleda J., Sala E., Pons J., Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:347-360.
34. Yanbaeva D.G., Dentener M.A., Creutzberg E.C., Wesseling G., Wouters E.F. Systemic effects of smoking. Chest 2007, 131:1557-1566.
35. de Kruif M.D., Lemaire L.C., Giebelen I.A., et al. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 2008, 34:518-522.
36. Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: role of comorbidities. Eur Respir J 2006, 28:1245-1257.
37. Rubattu S., Volpe M. The atrial natriuretic peptide: a changing view. J Hypertens 2001, 19:1923-1931.
38. Beishuizen A., Hartemink K.J., Vermes I., Groeneveld A.J. Circulating cardiovascular markers and mediators in acute illness: an update. Clin Chim Acta 2005, 354:21-34.
39. Masia M., Papassotiriou J., Morgenthaler N.G., Hernandez I., Shum C., Gutierrez F. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem 2007, 53:2193-2201.
40. Muller B., Prat C. Markers of acute inflammation in assessing and managing lower respiratory tract infections: focus on procalcitonin. Clin Microbiol Infect 2006, 12(Suppl 9):8-16.
41. Simon L., Gauvin F., Amre D.K., Saint-Louis P., Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004, 39:206-217.
42. Prat C., Dominguez J., Andreo F., et al. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect 2006, 52:169-177.
43. Wouters E.F. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:26-33.
44. Hurst J.R., Perera W.R., Wilkinson T.M., Donaldson G.C., Wedzicha J.A. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:71-78.
45. Hurst J.R., Donaldson G.C., Perera W.R., et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:867-874.
46. Deng J.C., Standiford T.J. The systemic response to lung infection. Clin Chest Med 2005, 26:1-9.
47. Donaldson G.C., Seemungal T.A., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57:847-852.
48. Sin D.D., Man S.F. Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Can J Physiol Pharmacol 2005, 83:8-13.
49. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P., Salcedo E., Navarro M., Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:925-931.
50. Inoue Y., Kawayama T., Iwanaga T., Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med 2009, 48:503-512.
51. Stolz D., Breidthardt T., Christ-Crain M., et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008, 133:1088-1094.
52. Bernasconi M., Christ-Crain M., Müller C., Müller B., Tamm M., Stolz D. MR-proANP predicts 2-year survival in patients admitted for acute exacerbation of COPD [Abstract]. Eur Respir J 2009, 34(Suppl 53):A4220.
53. Clerico A., Vittorini S., Passino C., Emdin M. New and emerging biomarkers of heart failure. Crit Rev Clin Lab Sci 2009, 46:107-128.
54. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.
55. Clerico A., Giannoni A., Prontera C., Giovannini S. High-sensitivity troponin: a new tool for pathophysiological investigation and clinical practice. Adv Clin Chem 2009, 49:1-30.